ClinicalTrials.gov
ClinicalTrials.gov Menu

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00826059
Recruitment Status : Completed
First Posted : January 21, 2009
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
BrainsGate

Brief Summary:
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.

Condition or disease Intervention/treatment Phase
Ischemic Stroke Device: Active Stimulation Device: Sham Stimulation Not Applicable

Detailed Description:

A multi-center, multinational, randomized, double blind, sham control, adjunctive to Standard of Care, parallel arm study and will include ongoing DSMB review of accumulated safety data.

Screening:

Since the treatment should be initiated within 24 hours from stroke onset, the screening window is limited and all procedures should be performed within this window.Subjects with Acute Ischemic Stroke will be screened upon arrival to the hospital. Since the treatment should be initiated between 8 and 24 hours from stroke onset, the screening window is limited and all procedures should be performed as soon as possible. All screened patients will be identified by patient number and will sign the informed consent prior to any study procedure initiation.

Period 1: Day 1-5

: Day 1- Eligible subjects will be randomized in a 1:1 (ISS Stimulation: Sham Control) ratio:

  • Group 1: Implantation and ISS Stimulation during five consecutive days & Standard of Care
  • Group 2: Sham Implantation and Sham Stimulation during five consecutive days & Standard of Care Subjects will be transferred to the implantation procedure facility and the implantation/sham implantation will be performed by a trained physician.

Following implantation, stimulation/sham stimulation will be delivered. Day 2-4 ISS / Sham Stimulation will be repeated during the following four consecutive days by trained personnel within 18-26 hours from preceding stimulation.

Day 5 / Day of Discharge. Following the last ISS /Sham Stimulation, explantation will be performed and the patients will be evaluated for safety and effectiveness.

Subjects will continue with Standard of Care as needed and will be released from the hospital upon investigator's judgment.

Period 2: Day of Discharge - 89±7 days During this period both groups (ISS Stimulation and Sham Control) will be treated according to Standard of Care either at the hospital, rehabilitation center or at home.

Scheduled visits will be performed on day 30±7 and day 60 ±7, which will include safety and effectiveness assessments.

Final Visit Day 90±7 days: The final visit will be performed at the study site and will include safety and effectiveness evaluations.

Patients will be contacted by study personnel via telephone on Day 180±7 and on Day 360±7 in order to assess their quality of life status.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke
Actual Study Start Date : January 2009
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018

Arm Intervention/treatment
Active Comparator: Active Stimulation

Implantation/ISS Stimulation during 5 consecutive days & Standard of Care (SoC).

Day 1: First stimulation initiated within 24 hours from stroke onset, following implantation completion. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.

Day 2-4: ISS Stimulation treatment sessions repeated daily. Each treatment will be initiated within 18-26 hours from the preceding treatment.

Day 5: Following completion of the last ISS Stimulation treatment session, imaging performed for assessing INS positioning and/or lesion. Implant removal procedure will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.

Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator.

Device: Active Stimulation
SPG stimulation and standard of care

Sham Comparator: Sham Stimulation

Sham Implantation and Sham Stimulation during 5 consecutive days & Standard of Care (SoC).

Day 1: First Sham stimulation initiated within 24 hours from stroke onset, following Sham implantation procedure. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.

Day 2-4: Sham Stimulation sessions repeated daily. Each Sham Stimulation will be initiated within 18-26 hours from the preceding treatment.

Day 5: Following completion of the last Sham Stimulation session, imaging performed for lesion assessment. Sham Implant removal will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.

Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator.

Device: Sham Stimulation
Sham SPG stimulation and standard of care




Primary Outcome Measures :
  1. Sliding Dichotomy modified Rankin Scale (mRS) at 3 months [ Time Frame: 90 days±7 days ]

    The primary efficacy endpoint is improvement beyond expectations on the modified Rankin Scale at 3 months (sliding dichotomy), assessed in primary populations of:

    1. modified intention to treat (mITT)
    2. confirmed cortical involvement (CCI), defined as baseline NIHSS ≥ 10 and signs of cortical involvement in baseline imaging (at least one of the following ASPECT regions: M1-M6, Insular Cortex).

    Type I Error is controlled at an overall level of 0.05 (two-sided) using the Hochberg method.



Other Outcome Measures:
  1. Subgroup analysis [ Time Frame: 90 days±7 days ]
    Primary parameters subgroup analysis by: NIHSS strata, lesion size, time from stroke onset strata, area of stroke, gender, age strata, Diabetes (Y/N), AFIB (Y/N) and side

  2. SIS-16 [ Time Frame: 90 days±7 days ]
    Stroke-related quality of life at 3 months according to the Stroke Impact Scale-16 (SIS-16)

  3. Dichotomy 0-2 mRS at 3 months [ Time Frame: 90 days±7 days ]
    Functional independence at 3 months (modified Rankin Scale 0-2)

  4. Dichotomy 0-3 mRS at 3 months [ Time Frame: 90 days±7 days ]
    Up to moderate disability but ambulatory at 3 months (modified Rankin Scale 0-3)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: Between 40 years and 80 years for male and 85 for female subjects
  2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories
  3. Imaging findings demonstrating signs of ischemia in the anterior circulation, consistent with the clinical diagnosis
  4. Baseline NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.
  5. Ability to initiate treatment within 8- 24 hours from stroke onset
  6. Signed informed consent from patient him/herself or legally authorized representative if applicable

Exclusion Criteria:

  1. Intracranial hemorrhage or hemorrhagic transformation
  2. Massive stroke
  3. Acute ischemic stroke in the posterior circulation
  4. Minor stroke
  5. Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke
  6. Previous stroke in the last 6 months or pre-existing disability
  7. Patients with bleeding propensity or any condition in the oral cavity that prevents implantation
  8. Clinical signs and symptoms or imaging evidence of bilateral stroke.
  9. Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke.
  10. Known cerebral arteriovenous malformation, cerebral aneurysm.
  11. Clinical suspicion of septic embolus.
  12. Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg)
  13. Serious systemic infection.
  14. Women known to be pregnant or having a positive or indeterminate pregnancy test.
  15. Patients with other implanted neural stimulator/ electronic devices (pacemakers).
  16. Life expectancy < 1 year from causes other than stroke.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00826059


Locations
United States, Florida
Intercoastal Medical Group
Sarasota, Florida, United States, 34232
United States, Illinois
Central DuPage Hospital
Winfield, Illinois, United States, 60190
United States, North Carolina
Guilford Neurologic Associates
Greensboro, North Carolina, United States, 27401
United States, Ohio
ProMedica Toledo Hospital
Toledo, Ohio, United States, 43606
United States, South Carolina
Palmetto Health Richland
Columbia, South Carolina, United States, 29203
United States, Tennessee
Erlanger Stroke Center
Chattanooga, Tennessee, United States, 37404
Georgia
Unimed Adjara Batumi Referral Hospital
Batumi, Georgia
Kutaisi Referral Hospital
Kutaisi, Georgia
Rustavi Central Hospital
Rustavi, Georgia, 3700
First University Clinic
Tbilisi, Georgia, 0141
High Technology Medical Center University Clinic LTD.
Tbilisi, Georgia, 0144
Emergency Neurology Clinic Neurology Ltd.
Tbilisi, Georgia
Zugdidi Referral Hospital
Zugdidi, Georgia, 2100
Germany
Erlangen University Clinic
Erlangen, Germany
Essen University Clinic
Essen, Germany
Heidelberg University Clinic
Heidelberg, Germany
Leipzig University Clinic
Leipzig, Germany
Spain
Hospital Vall d'Hebron
Barcelona, Spain
Sponsors and Collaborators
BrainsGate
Investigators
Study Director: Eyal Shay BrainsGate

Responsible Party: BrainsGate
ClinicalTrials.gov Identifier: NCT00826059     History of Changes
Other Study ID Numbers: CLP1000500
First Posted: January 21, 2009    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018

Keywords provided by BrainsGate:
acute ischemic stroke
randomized clinical trial
effectiveness
safety

Additional relevant MeSH terms:
Stroke
Ischemia
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia